|

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

RECRUITINGN/ASponsored by Adam S. Kibel, MD
Actively Recruiting
PhaseN/A
SponsorAdam S. Kibel, MD
Started2024-05-07
Est. completion2028-04-30
Eligibility
Age40 Years – 69 Years
SexMALE
Healthy vol.Accepted
Locations5 sites
View on ClinicalTrials.gov →

NCT06398639

Summary

The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer. The main questions it aims to answer are: * If genetic data related to prostate cancer used with MRI can identify higher-grade, potentially fatal prostate cancer * What age a MRI is useful clinically for prostate cancer screening * If deep learning methods used with MRI when the genetic risk of the man is known can more accurately predict significant cancers Participants will: * Get a prostate specific antigen (PSA) blood test * Get an mpMRI * Get the results of their genetic data to determine if they are considered high-, intermediate-, or low-risk for prostate cancer based on the trials genetic testing * Follow-up for this trial based on the participants risk and findings from the PSA test and mpMRI

Eligibility

Age: 40 Years – 69 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* They must have the ability to understand and the willingness to sign a written information consent document.
* Estimated life expectancy of greater than 10 years.
* No history of prostate cancer.
* Participants must be between 40-69 years of age. This is the age at which screening for prostate cancer is recommended. This is due to younger patients not being at risk for the disease and older patients not benefiting from diagnosis.
* No biopsy for prostate cancer within the past 5 years.
* No prostate MRI within the past 5 years.

Exclusion Criteria:

* Unwillingness to sign the informed consent form.
* Contraindication to biopsy such as uncorrectable bleeding or coagulation disorder.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit the safety of a biopsy and/or surgery.
* Unable to undergo an MRI.

Conditions3

CancerPolygenic Risk ScoreProstate Cancer

Locations5 sites

District of Columbia

1 site
Howard University Hospital
Washington D.C., District of Columbia, 20060
Pamela Coleman, MD

Maryland

2 sites
National Cancer Institute
Bethesda, Maryland, 20814
Peter A Pinto, MD204-858-7200pintop@mail.nih.gov
Walter Reed National Military Medical Center
Bethesda, Maryland, 20814
Gregory T Chesnut, MD301-319-2900gregory.chesnut@usuhs.edu

Massachusetts

2 sites
Massachusetts General Hospital
Boston, Massachusetts, 02114
Keyan Salari, MD, PhD857-238-3838ksalari@mgh.harvard.edu
Brigham and Women's Hospital
Boston, Massachusetts, 02155
Adam S Kibel, MD, MHCM617-525-7697akibel@bwh.harvard.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.